The S&P/TSX Venture Composite Index (INDEXTSI:JX) was back on top last week, rising 0.57 percent to reach 746.57 points. 
Ever since Donald Trump was elected president on November 8, markets have been on a roller coster ride, and the Canadian dollar has also fallen as investors look to buy into the US economy.
That being said, companies on the venture exchange also saw weekly percentage gains over the five-day trading period, with some gains reaching 60 percent.
The top five stocks for the week were:

Here’s a closer look at those companies:

American CuMo Mining

Topping last week’s 5 top TSXV stocks is American CuMo Mining who, according to its website has discovered one of the largest deposits of molybdenum, copper and silver in Idaho. The company has a 100 percent interest in the CuMo project. Most recently, American CuMo announced the signing of an agreement for a significant silver-copper property in Idaho.
Over the five-day period, shares of American CuMo saw an increase of 60 percent to reach $0.16.

Aurora Cannabis

Next on the lis tis Aurora Cannabis, who is focused on cultivating, harvesting and selling medicinal marijuana in Canada.
Last week, shares of the company increased 53.77 percent to reach $3.26. Although there has been no news regarding its share price increase, Aurora’s most recent news came on November 10 when it announced that its subsidiary, CanvasRx, had surpassed 13,000 registered patients.

Karmin Exploration

Karmin Exploration’s focus is on gold and zinc exploration in South American–particularly in Brazil and Peru. Shares of the company over last week’s five day period increased 42.31 percent to reach $0.37.
The company does not have any news regarding its share price increase, however on November 16 it announced that significant progress had been made at its Aripuana Zinc project in Brazil.

American Manganese

American Manganese is focused on its Artillery Peak property in Arizona, which is allegedly the biggest manganese deposit in the Southwest US. On November 10, the company announced that Phase 3 successful completion for upcycling and recycling EV lithium-ion battery coin cells can successfully be produced.
Last week, shares of American Manganese saw a 31.11 percent increase to reach $0.295.

Crystal Peak Minerals

Last but not least on the 5 top gaining TSXV stocks for the five-day period is Crystal Peak Minerals, a development-stage pre-revenue potash company.
Shares of Crystal Peak Minerals closed the week out at $0.35–a 22.81 percent increase over the week.
Data for 5 Top TSXV Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the mining and precious metals sectors are considered.
Don’t forget to follow us @INN_Resource for real-time news updates!
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure:American CuMo Mining and American Manganese are clients of the Investing News Network. This article is not paid-for content.
Top TSXV stocks in recent weeks:
5 Top TSXV Stocks: Copper Stocks on Top
5 Top TSXV Stocks: Gold Stocks Rally
5 Top TSXV Stocks: Gold Stocks on the Move
5 Top TSXV Stocks: Northern Lion Gold Tops the List
5 Top TSXV Stocks: Patriot One Technologies Boosts Over 400 Percent
5 Top TSXV Stocks: G4G Capital Tops the List For Second Week

Appointment of Financial Advisor

World High Life Plc (AQSE:LIFE)(OTCQB:WRHLF), is pleased to announce that it has appointed H&P Advisory Limited (“Hannam & Partners”) as financial advisor to the Company with immediate effect

Keep reading... Show less

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less